112 related articles for article (PubMed ID: 30939138)
1. A strategy for early detection of response to chemotherapy drugs based on treatment-related changes in the metabolome.
Amin S; Rattner J; Keramati MR; Farshidfar F; McNamara MG; Knox JJ; Kopciuk K; Vogel HJ; Bathe OF
PLoS One; 2019; 14(4):e0213942. PubMed ID: 30939138
[TBL] [Abstract][Full Text] [Related]
2. Effects of glaucocalyxin A on human liver cancer cells as revealed by GC/MS- and LC/MS-based metabolic profiling.
Liu Y; Lu S; Zhao L; Dong X; Zhu Z; Jin Y; Chen H; Lu F; Hong Z; Chai Y
Anal Bioanal Chem; 2018 May; 410(14):3325-3335. PubMed ID: 29651531
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.
Caruso S; Calatayud AL; Pilet J; La Bella T; Rekik S; Imbeaud S; Letouzé E; Meunier L; Bayard Q; Rohr-Udilova N; Péneau C; Grasl-Kraupp B; de Koning L; Ouine B; Bioulac-Sage P; Couchy G; Calderaro J; Nault JC; Zucman-Rossi J; Rebouissou S
Gastroenterology; 2019 Sep; 157(3):760-776. PubMed ID: 31063779
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
7. Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma.
Gao R; Cheng J; Fan C; Shi X; Cao Y; Sun B; Ding H; Hu C; Dong F; Yan X
Sci Rep; 2015 Dec; 5():18175. PubMed ID: 26658617
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
Teufel M; Seidel H; Köchert K; Meinhardt G; Finn RS; Llovet JM; Bruix J
Gastroenterology; 2019 May; 156(6):1731-1741. PubMed ID: 30738047
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
10. Early detection of treatment futility in patients with metastatic colorectal cancer.
Rattner JI; Kopciuk KA; Vogel HJ; Tang PA; Shapiro JD; Tu D; Jonker DJ; Siu LL; O'Callaghan CJ; Bathe OF
Oncotarget; 2022; 13():61-72. PubMed ID: 35028011
[TBL] [Abstract][Full Text] [Related]
11. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
[TBL] [Abstract][Full Text] [Related]
12. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
[TBL] [Abstract][Full Text] [Related]
13. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells.
Chiba T; Yokosuka O; Fukai K; Kojima H; Tada M; Arai M; Imazeki F; Saisho H
Oncology; 2004; 66(6):481-91. PubMed ID: 15452378
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic study of natrin-induced apoptosis in SMMC-7721 hepatocellular carcinoma cells by ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry.
Lu S; Lu R; Song H; Wu J; Liu X; Zhou X; Yang J; Zhang H; Tang C; Guo H; Hu J; Mao G; Lin H; Su Z; Zheng H
Int J Biol Macromol; 2019 Mar; 124():1264-1273. PubMed ID: 30508545
[TBL] [Abstract][Full Text] [Related]
15. [Hepatocellular carcinoma].
Kondo S; Ueno H; Morizane C; Okusaka T
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
[TBL] [Abstract][Full Text] [Related]
16. Metabolic profiling study of shikonin's cytotoxic activity in the Huh7 human hepatoma cell line.
Spyrelli ED; Kyriazou AV; Virgiliou C; Nakas A; Deda O; Papageorgiou VP; Assimopoulou AN; Gika HG
Mol Biosyst; 2017 May; 13(5):841-851. PubMed ID: 28265634
[TBL] [Abstract][Full Text] [Related]
17. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
18. RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo.
Wang W; Cheng J; Qin JJ; Voruganti S; Nag S; Fan J; Gao Q; Zhang R
Oncotarget; 2014 Nov; 5(22):11604-19. PubMed ID: 25344099
[TBL] [Abstract][Full Text] [Related]
19. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
